×

PUBLICATION IN ACCORDANCE WITH ARTICLE 15 OF THE BELGIAN LAW OF 2 MAY 2007 ON THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

REGULATED INFORMATION

Ghent/Zwijnaarde, Belgium, June 10, 2016 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, as a result of the closing of its private placement which raised €74.2 million on 1 June 2016, the following information in accordance with article 15 of the Law of 2 May 2007 on the publication of major shareholdings in issuers whose shares are admitted to trading on a regulated market (the "Transparency Law").

As of today, Ablynx's total share capital amounts to 113,771,789.41. The total number of securities conferring voting rights is 60,870,926 which is also the total number of voting rights (the "denominator"). The total number of rights (warrants) to subscribe to not yet issued securities conferring voting rights is 2,672,222 which equals the total number of voting rights that may result from the exercise of these warrants. Currently 1,000 convertible bonds are outstanding entitling the holders thereof to 7,733,952 shares of the Company in the aggregate, upon conversion of such convertible bonds.

Total amount of share capital €113,771,789.41
Total number of securities conferring voting rights 60,870,926
Total number of voting rights (denominator) 60,870,926
Total number of warrants, in number of shares 2,672,222
Maximum additional number of shares after conversion of bonds 7,733,952
Total number of diluted shares 71,277,100

About Ablynx

Ablynx is a biopharmaceutical company engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 40 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Genzyme, Merck & Co, Inc., Merck Serono, Novartis and Novo Nordisk. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

For more information, please contact
Ablynx:
Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: edwin.moses@ablynx.com

Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch@ablynx.com
Follow us on Twitter @AblynxABLX

Ablynx media/analyst relations
FTI Consulting:
Julia Phillips, Brett Pollard, Mo Noonan, Matthew Moss
t: +44 20 3727 1000
e: ablynx@fticonsulting.com

pdf format of the press release http://hugin.info/137912/R/2019623/749870.pdf

HUG#2019623

Source:Ablynx